• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白线性化连接:定点抗体药物偶联物。

Streamlined Expressed Protein Ligation: Site-Specific Antibody-Drug Conjugate.

机构信息

ProteoDesign, Barcelona, Spain.

出版信息

Methods Mol Biol. 2020;2133:183-200. doi: 10.1007/978-1-0716-0434-2_9.

DOI:10.1007/978-1-0716-0434-2_9
PMID:32144668
Abstract

Protein semisynthesis is a powerful tool for studying proteins and has contributed to a better understanding of protein structure and function and also driven innovations in protein science. Expressed protein ligation (EPL) is a widely used method to generate chemically modified proteins. However, EPL has some limitations, particularly relevant to modify challenging proteins such as antibodies. The method termed streamlined expressed protein ligation (SEPL) overcomes some of the problems of EPL, and other methods of protein semisynthesis, to generate challenging modified proteins such as antibody-drug conjugates (ADCs). ADCs targeting highly cytotoxic molecules to cancer cells, offer an attractive strategy to selectively eliminate tumor cells with improved therapeutic index than the antibodies or cytotoxic molecules themselves. Despite the potential of ADCs, the development of such complex molecules is challenging. We provide here protocols to prepare site-specifically modified ADCs by streamlined expressed protein ligation (SEPL), which does not require the incorporation of unnatural modifications into the antibody. Therefore, fully native antibodies, with only the desired cytotoxic molecules attached, can be generated.

摘要

蛋白质半合成是研究蛋白质的有力工具,有助于更好地理解蛋白质的结构和功能,并推动蛋白质科学的创新。表达蛋白连接(EPL)是一种广泛用于生成化学修饰蛋白的方法。然而,EPL 存在一些局限性,特别是在修饰具有挑战性的蛋白如抗体时更为明显。被称为简化表达蛋白连接(SEPL)的方法克服了 EPL 及其他蛋白半合成方法的一些问题,可用于生成具有挑战性的修饰蛋白,如抗体药物偶联物(ADC)。ADC 靶向高细胞毒性分子到癌细胞,提供了一种有吸引力的策略,与抗体或细胞毒性分子本身相比,选择性消除肿瘤细胞,提高治疗指数。尽管 ADC 具有潜力,但开发此类复杂分子具有挑战性。我们在此提供通过简化表达蛋白连接(SEPL)制备定点修饰 ADC 的方案,该方法不需要将非天然修饰物掺入抗体中。因此,可以生成仅附着所需细胞毒性分子的完全天然抗体。

相似文献

1
Streamlined Expressed Protein Ligation: Site-Specific Antibody-Drug Conjugate.蛋白线性化连接:定点抗体药物偶联物。
Methods Mol Biol. 2020;2133:183-200. doi: 10.1007/978-1-0716-0434-2_9.
2
Site-specific modification of ED-B-targeting antibody using intein-fusion technology.利用内含肽融合技术对 ED-B 靶向抗体进行定点修饰。
BMC Biotechnol. 2011 Jul 21;11:76. doi: 10.1186/1472-6750-11-76.
3
Site-Specific Antibody Drug Conjugates Using Streamlined Expressed Protein Ligation.使用简化表达蛋白连接的靶向抗体药物偶联物。
Bioconjug Chem. 2018 Nov 21;29(11):3503-3508. doi: 10.1021/acs.bioconjchem.8b00630. Epub 2018 Oct 22.
4
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.利用非天然氨基酸合成定点抗体药物偶联物。
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16101-6. doi: 10.1073/pnas.1211023109. Epub 2012 Sep 17.
5
Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.免疫球蛋白G1和免疫球蛋白G2抗体-药物偶联物的半胱氨酸连接缀合谱的表征
J Pharm Sci. 2015 Apr;104(4):1362-72. doi: 10.1002/jps.24338. Epub 2015 Jan 28.
6
Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar.通过工程化糖基转移酶和化学反应性糖进行位点特异性抗体-药物偶联
MAbs. 2014;6(5):1190-200. doi: 10.4161/mabs.29889. Epub 2014 Oct 30.
7
Identification, Characterization, and Optimization of Split Inteins.分裂整合酶的鉴定、特性分析和优化。
Methods Mol Biol. 2020;2133:31-54. doi: 10.1007/978-1-0716-0434-2_3.
8
Expressed Protein Ligation: General Experimental Protocols.蛋白质定点连接技术:一般实验方案
Methods Mol Biol. 2020;2133:75-117. doi: 10.1007/978-1-0716-0434-2_5.
9
Fused Split Inteins: Tools for Introducing Multiple Protein Modifications.融合分裂内含肽:引入多种蛋白质修饰的工具。
Methods Mol Biol. 2020;2133:163-181. doi: 10.1007/978-1-0716-0434-2_8.
10
Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.利用第二代马来酰亚胺将 Auristatins 定点连接到工程化 scFv 上,用于体外靶向 HER2 阳性乳腺癌。
Bioconjug Chem. 2018 Nov 21;29(11):3516-3521. doi: 10.1021/acs.bioconjchem.8b00668. Epub 2018 Oct 25.

引用本文的文献

1
Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules.将血脑屏障肽穿梭体与Fc结构域偶联用于治疗性生物分子的脑内递送。
ACS Med Chem Lett. 2021 Sep 2;12(11):1663-1668. doi: 10.1021/acsmedchemlett.1c00225. eCollection 2021 Nov 11.
2
New Technologies Bloom Together for Bettering Cancer Drug Conjugates.新技术齐绽放,助力癌症药物偶联物研发
Pharmacol Rev. 2022 Jul;74(3):680-711. doi: 10.1124/pharmrev.121.000499.